Skip to NavigationSkip to content

News

0
NovAliX, a drug discovery-focused contract research organisation, and Chemical.AI, an artificial intelligence (AI) company, have announced a...
0
The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in...
0
Digital health platform Curelator has announced new data that shows a lack of association between increased stress and migraine attacks.
0
Genentech has announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its...

Features

In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the cancer drugs...